Lawsuits are being filed against Pfizer, the manufacturer of the injectable contraceptive Depo-Provera (medroxyprogesterone acetate), due to emerging medical evidence linking long-term use of the drug to an increased risk of brain tumors, specifically meningiomas.

Key reasons for the litigation include:

Inadequate Warnings: Plaintiffs allege that Pfizer failed to provide sufficient warnings to users and healthcare providers about the potential for developing hormone-sensitive brain tumors, despite scientific studies indicating a link.

Scientific Evidence: Research, including a 2024 study, found that prolonged use of progestin injectables like Depo-Provera could more than double the risk of meningiomas. Other studies suggested even higher risks for those using the drug for more than a year.

Product Liability: Claims are based on theories of design defects and the manufacturer’s failure to disclose safety information. Because these tumors are often hormone-receptor positive, the progestin in the contraceptive is believed to promote tumor growth.

To manage these cases efficiently, federal courts have consolidated the claims into multidistrict litigation (MDL No. 3140) to address common issues regarding Pfizer’s liability and the drug’s safety profile.


Related FAQs